Business Context and Reporting Period
This Form 8-K was filed by LIFECORE BIOMEDICAL, INC. on January 11, 2023. The filing addresses a regulatory compliance issue regarding the company's listing status on The Nasdaq Global Select Market.
Key Financial Metrics
This filing is a current report regarding a listing notice and does not contain financial performance data. The text does not provide values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes
The primary material event is the receipt of a notification letter from Nasdaq indicating the Company is not in compliance with Nasdaq Listing Rule 5250(c)(1). This non-compliance is due to a delay in filing the Quarterly Report on Form 10-Q for the period ended November 27, 2022.
Outlook, Risks, and Management Commentary
- Immediate Impact: The notification has no immediate effect on the listing or trading of the Company's common stock.
- Compliance Timeline: The Company has 60 calendar days (until March 12, 2023) to submit a plan to regain compliance.
- Extension Possibility: If a plan is accepted, Nasdaq may grant up to 180 calendar days from the original due date (until July 5, 2023) to file the Form 10-Q.
- Management Action: The Company states it is working diligently to complete the Form 10-Q and plans to file it as promptly as possible.
- Risks: Forward-looking statements highlight risks regarding the ability to respond to Nasdaq inquiries, regain compliance, and the potential for the Form 10-Q filing to take longer than expected.
Investor Verification Checklist
- Verify the status of the Form 10-Q for the period ended November 27, 2022, and whether it has been filed.
- Monitor the submission of a compliance plan to Nasdaq by the March 12, 2023 deadline.
- Check for any subsequent communications from Nasdaq regarding the acceptance of the compliance plan or potential delisting.
- Review the most recent Annual Report on Form 10-K for additional risk factors related to regulatory compliance.